StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$51.35+0.38 (+0.75%)

Close on Nov 19, 2026

Genmab A/S TEPEZZA Royalty Revenue (from Amgen) by Quarter

TEPEZZA Royalty Revenue (from Amgen) ($M)

Genmab A/S TEPEZZA Royalty Revenue (from Amgen): $36M in Q3 2026, up 20.0% from a year earlier. That is the highest of the 11 quarters on record here.

Latest, Q3 2026
36
Period ended Sep 30, 2026
Change on a year earlier
+20.0%
30 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“|| TEPEZZA | 36 | 30 | 93 | 75”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

Mid-single-digit royalty on worldwide net sales of teprotumumab-trbw (TEPEZZA) for thyroid eye disease.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Genmab A/S TEPEZZA Royalty Revenue (from Amgen) ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/royalties-tepezza

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?